🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Tenet Healthcare Rides On Inorganic Growth, Reduces Leverage

Published 03/04/2020, 08:31 PM
Updated 07/09/2023, 06:31 AM
CI
-
AET
-
HUM
-
THC
-
UNH
-

Tenet Healthcare Corporation (NYSE:THC) is taking initiatives to expand through its inorganic growth policy as well as reduce costs. The company has also been successful in lowering its leverage level over the last few quarters.

Over the years, this leading healthcare services company constantly strengthened its position in the market by tying up with industry biggies like Blue Cross Blue Shield of Texas, Cigna Corporation (NYSE:CI) , Aetna (NYSE:AET), UnitedHealth Group Incorporated (NYSE:UNH) , Humana Inc. (NYSE:HUM) , et al. Its solid inorganic growth story, aimed at boosting scale of business, operating capacity and expanding its geographical presence, continued in 2019 wherein it acquired 10 outpatient businesses (all of which are owned by United Surgical Partners International) and various physician practices for a deal value of $25 million.

The company focuses on divesting its non-core and unprofitable business units to repay its debt and maintain financial liquidity. A number of divestitures carried out over the past three years have streamlined its operations and generated funds to pay down debt. The company’s strategic priorities include completing hospital divestitures and allocating capital to higher return on investments The company is on course to spin-off of its Conifer business into an independent publicly-traded company, which is expected to close by the end of 2021. The company is likely to decrease its debt burden by using the proceeds from this transaction.

After enduring high level of operating expenses for a number of years, the company took cost-saving measures, consisting of headcount cut and the renegotiation of contracts with suppliers and vendors. Tenet Healthcare expects better expense management to help control its costs.

Its leverage level has also been declining with long-term debt dipping 0.5% year over year in 2019. Given its restructuring plans, we expect the company to lower its debt level further.

The company’s recently-provided 2020 guidance also looks encouraging. It expects adjusted earnings per share from continuing operations between $2.69 and $3.35. Tenet Healthcare expects net operating revenues of $19.1-$19.5 billion, the midpoint indicating a rise of 4% from the 2019 reported figure. Adjusted EBITDA is estimated between $2.8 billion and $2.9 billion, the midpoint suggesting a 5.3% increase from the 2019 reported number on the back of sustained organic volume expansion on its hospital and ambulatory platforms. The company projects adjusted net cash provided by operating activities of $1.5-$1.7 billion, implying a 30% hike from the 2019 reported figure.

Given these positives, this Zacks Rank #3 (Hold) stock has surged 45.4% in the past six months against the industry’s decline of 1.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>



UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Cigna Corporation (CI): Free Stock Analysis Report

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.